Lys250
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.0
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys250  -  BUB1B (human)

Site Information
IRVGGALkAPSQNRG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 25174702

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 1 ) , immunoprecipitation ( 1 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
bone cancer ( 1 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 1 ) , HCT116 (intestinal) ( 1 ) , HeLa (cervical) ( 1 ) , U2OS (bone cell) ( 1 )

Upstream Regulation
Treatments:
caffeine ( 1 ) , DEVD-CHO ( 1 ) , medium change ( 1 ) , MG132 ( 1 ) , nocodazole ( 1 ) , taxol ( 1 ) , trichostatin_A ( 1 )

Downstream Regulation
Effects of modification on BUB1B:
protein degradation ( 1 )
Effects of modification on biological processes:
cell cycle regulation ( 1 )

References 

1

Yang F, et al. (2012) BubR1 is modified by sumoylation during mitotic progression. J Biol Chem 287, 4875-82
22167194   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.